Skip to main content
SpringerLink
Log in

Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The nitroimidazole, RSU1069, has been shown to have a very high differential toxicity towards hypoxic cells compared to oxic cells both inin vitro andin vivo experimental conditions. However, in the clinic it was found to cause severe emesis and had to be withdrawn. After an extensive drug development programme an analogue of RSU1069, RB6145, which acts as a pro-drug for RSU1069, was found to be the most suitable candidate for further investigation. Inin vivo studies with murine tumour models, when RB6145 was used in combination with X-rays it was shown to produce a similar level of toxicity towards hypoxic cells as that observed for RSU1069. Its activity was the same whether it was administered interperitoneally or orally and the same level of anti-tumour effect was observed if the drug was given before or after X-rays. RB6145 is better tolerated systemically in mice than RSU1069 and canine studies have shown that it is less emetic than the parent drug.

Bioreductive drugs can also be used in combination with treatments that preferentially increase tumour hypoxia. Photodynamic therapy (PDT) causes extensive vascular damage in tumours. If either RSU1069 or RB6145 are administered during PDT, very large increases in the growth delay induced by PDT alone are seen for the RIF-1 murine tumour.

RB6145 has been accepted for clinical toxicity trials with the prospect of using it in combination with X-rays. In the future it may also be of clinical use with treatments such as PDT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dische S: Hyperbaric oxygen: the medical Research Council Trials and their clinical significance. Br J Radiol 51: 888–894, 1979

    Google Scholar 

  2. Adams GE: Hypoxic cell radiosensitizers for radiotherapy. In: Becker F (ed) Cancer: a comprehensive treatise. Vol. 6. Plenum Press, New York, 1977, pp181–223

    Google Scholar 

  3. Sutherland RM: Selective chemotherapy of non-cycling cells in anin vitro tumor model. Cancer Res 34: 3501–3503, 1974

    Google Scholar 

  4. Foster JL, Willson RL: Radiosensitization of anoxic cells by metronidazole. Br J Radiol 46: 234–235, 1973

    Google Scholar 

  5. Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC: The hypoxic tumour cell: a target for selective cancer chemotherapy. Biochem Pharmac 29: 1–8, 1980

    Google Scholar 

  6. Adams GE, Ahmed I, Sheldon PW, Stratford IJ: Radiation sensitization and chemopotentiation: RSU1069 a compound more efficient than misonidazolein vitro andin vivo. Br J Cancer 49: 571–578, 1984

    Google Scholar 

  7. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC: Chemotherapeutic attack of hypoxic cells by the bioreductive agent, mitomycin-C. Cancer Res 45: 3642–3645, 1985

    Google Scholar 

  8. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW: SR4233, a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239–1242, 1986

    Google Scholar 

  9. Stratford IJ, Stephens MA: The differential hypoxic cytotoxicity of bioreductive agents determinedin vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973–976, 1989

    Google Scholar 

  10. Workman P, Walton MI: Enzyme related bioreductive drug development. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective activation of drugs by redox processes. Plenum Press, New York, 1990, pp173–191

    Google Scholar 

  11. Adams GE, Fowler JF: Nitroimidazoles as hypoxic cell sensitizersin vitro andin vivo. In: Modification of radiosensitivity of biological systems. I.A.E.A. Vienna, 1976, pp103–117

    Google Scholar 

  12. Adams GE: Redox, radiation and reductive bioactivation. Radiat Res 132: 129–139, 1992

    Google Scholar 

  13. Asquith JC, Watts ME, Patel K, Smithen CE, Adams GE: Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cellsin vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 60: 108–118, 1974

    Google Scholar 

  14. Dische S, Gray AJ, Zanelli GD: Clinical testing of the radiosensitizer Ro-07-0582. II. Radiosensitization of normal and hypoxic skin. Clin Radiol 27: 159–166, 1976

    Google Scholar 

  15. Gray AJ, Dische S, Adams GE, Flockhart IR, Foster JL: Clinical testing of the radiosensitizer Ro-07-0582. I. Dose, tolerance, serum and tumor concentrations. Clin Radiol 27: 151–157, 1976

    Google Scholar 

  16. Thomlinson RH, Dische S, Gray AJ, Errington LM: Clinical testing of the radio sensitizer Ro-07-0582. III. Response of tumours. Clin Radiol 27: 167–174, 1976

    Google Scholar 

  17. Overgaard J, Hansen SH, Anderson AP, Hjelm-Handsen M, Jorgensen K, Sandberg K, Rygard J, Jensen RH, Peterson M: Misonidazole as an adjunct to radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx. In: Karcher KH, Kogelnik HD, Szepesi T (eds) Progress in radio-oncology III, Proceedings of the 3rd International Meeting on Progress in Radio-oncology, March 1985. I.C.R.O., Vienna, 1987, pp137–147

    Google Scholar 

  18. Wardman P, Clarke ED, Jacobs RS, Minchinton A, Stratford MRL, Watts ME, Woodcock M, Moazzam M, Parrick J, Wallace RG, Smithen CE: Development of hypoxic cell radiosensitizers. The second and third generations. In: Brady LW (ed) Radiation Sensitizers. Cancer Management, Vol 5. Masson Publishing, USA, 1980, pp83–90

    Google Scholar 

  19. Adams GE, Flockart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME: Electron affinic radiosensitizers. VII. A correlation between structures, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res 67: 9–20, 1976

    Google Scholar 

  20. Brown JM, Lee WW: Pharmacokinetic considerations in radiosensitizer development. In: Brady LW (ed) Radiation Sensitizers. Cancer Management, Vol 5. Masson Publishing USA, 1980, pp2–13

  21. Chassagne D, Sancho-Garnier H, Charreau I, Eschwege F, Malaise EP: Progress report of a phase II and phase III trial with etanidazole (SR2508) - a multicentre European study. Radiother Oncol Suppl 20: 121–128, 1991

    Google Scholar 

  22. Wasserman TH, Lee DJ, Cosmatos D, Coleman N, Phillips T, Davis L, Marcial V, Stetz J: Clinical trials with Etanidazole (SR-2508) by the radiation therapy oncology group (RTOG). Radiother Oncol Suppl 20: 129–136, 1991

    Google Scholar 

  23. Ahmed I, Jenkins TC, Walling JM, Stratford IJ, Sheldon PW, Adams GE, Fielden EM: Analogues of RSU1069: Radiosensitization and toxicityin vitro andin vivo. Int J Radiat Oncol Biol Phys 12: 1079–1081, 1986

    Google Scholar 

  24. Hill RP, Gulyas S, Whitmore GF: Studies of thein vivo andin vitro cytotoxicity of the drug RSU1069. Br J Cancer 53: 743–748, 1986

    Google Scholar 

  25. Stratford IJ, Adams GE, Godden J, Howells N: Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU1069in vivo. Int J Radiat Biol 55: 411–422, 1989

    Google Scholar 

  26. Stratford IJ, Adams GE, Bremner JCM, Ding L, Edwards HE, Keohane A, Stephens MA: The assessment of bioreductive drug toxicityin vitro andin vivo. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series. Plenum Press, New York, 1990, pp203–212

    Google Scholar 

  27. Whitmore GF, Gulyas S: Studies on the toxicity of RSU1069. Int J Radiat Oncol Biol Phys 12: 1219–1222, 1986

    Google Scholar 

  28. O'Neill P, McNeil SS, Jenkins TC: Induction of DNA crosslinksin vitro upon reduction of the nitroimidazole-aziridines RSU1069 and RSU1131. Biochem Pharmac 36: 1787–1791, 1987

    Google Scholar 

  29. O'Neill P, Cunniffe SMT: Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine. Int J Radiat Oncol Biol Phys 16: 963–966, 1989

    Google Scholar 

  30. O'Neill P, Jenner TJ, Sapora O, Crump PW, Cunniffe SMT, Fielden EM: The role of DNA damage in the bioreductive action of 2-nitroimidazoles. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series. Plenum Press, New York, 1990, pp53–61

    Google Scholar 

  31. Walton MI, Wolf CR, Workman P: Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16: 893, 1986

    Google Scholar 

  32. Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC: The radiosensitizing and cytotoxic effects of RSU1069 on hypoxic cells in a murine tumour. Int J Radiat Oncol Biol Phys 12: 1091–1095, 1986

    Google Scholar 

  33. Horwich A, Holliday SB, Deacon JM, Peckham MJ: A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitizer, RSU1069. Br J Radiol 59: 1238–1240, 1986

    Google Scholar 

  34. Fielden EM, Adams GE, Cole S, Naylor MA, O'Neill P, Stephens MA, Stratford IJ: Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs. Int J Radiat Oncol Biol Phys 22: 707–711, 1992

    Google Scholar 

  35. Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM Suto MJ, Stier MA: Synthesis and evaluation of α-[[(2-Haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of α-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33: 2603–2610, 1990

    Google Scholar 

  36. Foster JL, Conroy PJ, Searle AJ, Willson RL: Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer 33: 485–490, 1976

    Google Scholar 

  37. Chaplin DJ: Potentiation of RSU1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer 54: 727–731, 1986

    Google Scholar 

  38. Chaplin DJ, Acker B: Potentiation of RSU1069 tumour cytotoxicity by hydralazine: a new approach to selective therapy. Int J Radiat Oncol Biol Phys 13: 579–585, 1987

    Google Scholar 

  39. Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J: Dual function nitroimidazoles less toxic than RSU1069: selection of candidate drugs for clinical trial (RB6145 and/or PD130908). Int J Radiat Oncol Biol Phys 22: 545–548, 1990

    Google Scholar 

  40. Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE: Oral (p.o.) dosing with RSU1069 and RB6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice. Int J Radiat Oncol Biol Phys 21: 387–395, 1991

    Google Scholar 

  41. Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J: Dual function nitroimidazoles less toxic than RSU1069: selection of candidate drugs for clinical trial (RB6145 and/or PD130908). Int J Radiat Oncol Biol Phys 22: 545–548, 1992

    Google Scholar 

  42. Clement.JJ, Wodinsky I, Johnson RK, Silveira DM: Radiosensitization and pharmacokinetics of oral and intraperitoneal misonidazole and desmethylmisonidazole in murine tumours. In: Brady LW (ed) Radiation Sensitizers. Masson Publishing, New York, 1980: 232–238

    Google Scholar 

  43. Coleman CN, Lee WW, Constine LS, Brown JM: The development of an oral pro-drug, SR-2545 of the 2-nitroimidazole radiosensitizer SR 2508. Int J Radiat Oncol Biol Phys 8: 431–434, 1982

    Google Scholar 

  44. Walton MI, Workman P: Pharmacokinetics and metabolism of the mixed function hypoxic cell sensitizer prototype RSU1069 in mice. Cancer Chemother Pharmacol 22: 275–288, 1988

    Google Scholar 

  45. Binger M, Workman P: Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB6145) of the mixed-function hypoxic cell sensitizer/cytotoxin a-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU1069). Cancer Chemother Pharmacol 29: 37–47, 1991

    Google Scholar 

  46. Sebolt-Leopold JS, Vincent PW, Benings KA, Elliott WL, Leopold WR, Stier MA, Suto MJ: Pharmacologic/pharmacokinetic evaluation of emesis induced by analogues of RSU1069 and its control by anti-emetic drugs. Int J Radiat Oncol Biol Phys 22: 549–551, 1992

    Google Scholar 

  47. Chaplin DJ: The effect of therapy on tumour vascular function. Int J Radiat Biol 60: 311–325, 1991

    Google Scholar 

  48. Denekamp J, Harris SR: Tests on two electron affinic radiosensitizersin vivo using regrowth of an experimental carcinoma. Br J Radiol 48: 571, 1975

    Google Scholar 

  49. Bremner JCM, Stratford IJ, Bowler J, Adams GE: Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717–721, 1990

    Google Scholar 

  50. Cole S, Stratford IJ, Adams GE: Manipulation of oxygenation in a human melanoma xenograft to exploit the bioreductive toxicity of RSU1069. Int J Radiat Biol 56: 587, 1989

    Google Scholar 

  51. Chaplin DJ: Postirradiation modification of tumour bloodflow: a method to increase the effectiveness of chemical radiosensitizers. Radiat Res 292, 1988

  52. Brown JM: Exploitation of bioreductive agents with vasoactive drugs. In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Radiation Research, Vol 2. Taylor and Francis, London, 1987, pp 719–724

    Google Scholar 

  53. Horsman MR, Christensen KL, Overgaard J: Hydralazine induced enhancement of hyperthermic damage in the C3H mammary carcinomain vivo. Int J Hyperthermia 5: 123–136, 1989

    Google Scholar 

  54. Guichard M, Lespinasse F, Trotter M, Durand R, Chaplin DG: The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts. Radiother Oncol 20: 117–123, 1991

    Google Scholar 

  55. Jirtle RL: Chemical modification of tumour blood flow. Int J Hyperthermia 4: 355–371

  56. Honness D, Bleehen NM: Effect of two tumour blood flow modifiers in KHT tumour and normal tissue in mice. In: Moore JV, West DC (eds) Vasculature as a target for anticancer therapy. 16th L.H. Gray Conference Proceedings, 1991, pp249–253

  57. Stratford IJ, Adams GE, Godden J, Howells N, Nolan J, Timpson N: Potentiation of the anti-tumour effect of melphalan by the vaso-active drug hydralazine. Br J Cancer 58: 122–127, 1988

    Google Scholar 

  58. Dunn JF, Frostick S, Adams GE, Stratford IJ, Howells N, Hogan G, Radda GK: Induction of tumour hypoxia by a vasoactive agent: A combined NMR and radiobiological study. FEBS Lett 249: 343–347, 1989

    Google Scholar 

  59. Bremner JCM, Stratford IJ, Bowler J, Adams GE: Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717–721, 1990

    Google Scholar 

  60. Hirst DG, Hill SA: The control of tumour oxygenation in mice: the importance of tumour site. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, New York, 1990, pp223–228

    Google Scholar 

  61. Hirst DG, Hirst VK, Shaffi KM, Prise VE, Joiner B: The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol 60:211–218, 1991

    Google Scholar 

  62. Acker B, Lentle B, Chaplin DJ: The effect of hydralazine on blood flow in human tumours. In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Radiation Research, Vol 1. Taylor and Francis, London, 1987, p297

    Google Scholar 

  63. Rowell NP, Flower MA, McCready VR, Cronin B, Horwich A: The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol 18: 283–292, 1990

    Google Scholar 

  64. Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S, Wooton R: Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol 82: 397–401, 1984

    Google Scholar 

  65. Adams GE, Barnes DHW, DuBoulay C, Loutit JF, ColeS, Sheldon PW, Stratford IJ, van den Aardweg GJMJ, Hopewell JW, White RD, Kneen G, Nethersell ABW, Edwards JC: Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin - implications for therapy. Int J Radiat Oncol Biol Phys 12: 1299–1302, 1986

    Google Scholar 

  66. Adams GE, Stratford IJ, Nethersell ABW, White RD: Induction of severe tumour hypoxia by the modifiers of oxygen affinity of hemoglobin. Int J Radiat Oncol Biol Phys 16: 1179–1182, 1989

    Google Scholar 

  67. Bedford P, Nethersell ABW, Stratford IJ, Cole S, Bremner JCM,Adams GE: Potentiation of bioreductive drugs by BW12c. J Canc Res Clin Oncol 16: (suppl 1): 621, 1990

    Google Scholar 

  68. Honness D, White RD, Nethersell ABW, Bleehen NM: Effects of the manipulation of oxyhemoglobin status by BW12c on tumour thermosensitivity and on blood flow in tumour and normal tissue in mice. Int J Radiat Oncol Biol Phys 16: 1187–1191, 1989

    Google Scholar 

  69. Bremner JCM, Counsell CJR, Edwards HE, Stratford IJ, Adams GE, Nethersell ABW, Bedford P: Monitoring metabolic responses after induction of hypoxia in the KHT tumour using31PNMR spectroscopy. Int J Radiat Biol 60: 363–367, 1991

    Google Scholar 

  70. Cole S, Robbins L: Manipulation of oxygenation in a human tumour xenograft with BW12c or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU1069. Radiother Oncol 16: 235, 1989

    Google Scholar 

  71. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis in tumours. Proc Natl Acad Sci USA 72: 3669–3670, 1975

    Google Scholar 

  72. Smith GP, Calveley SB, Smith MJ, Baguley BC: Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209–1211,1987

    Google Scholar 

  73. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P: Anti-tumour effects of recombinant human interleukin 1a in RIF-1 and PancO2 solid tumours. Cancer Res 48:6011–6016, 1988

    Google Scholar 

  74. Bibby MC, Double JA, Phillips RM, Quinn PKM: Flavone acetic acid: is vascular shutdown the crucial mechanism of action? Int J Radiat Biol 60: 395–399, 1991

    Google Scholar 

  75. Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J, Kikuchi H: Recombinant human tumour necrosis factor - a: evidence of an indirect mode of anti-tumour activity. Cancer Res 47: 3707–3711, 1987

    Google Scholar 

  76. Finlay GJ, Smith GP, Fray LM, Baguley BC: Effects of flavone acetic acid (NSC347512) on Lewislung carcinoma: evidence of an indirect effect. J Nat Cancer Inst 80: 241–245, 1988

    Google Scholar 

  77. Edwards HE, Bremner JCM, Stratford IJ: Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. Int J Radiat Biol 59: 419–432, 1991

    Google Scholar 

  78. Edwards HE, Bremner JCM, Stratford IJ: Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol 60: 373–377, 1991

    Google Scholar 

  79. Stratford IJ: Bioreductive drugs in cancer therapy. Br J Radiol Suppl 24: 128–136, 1992

    Google Scholar 

  80. Kerr DJ, Maughan T, Newland E, Rustin G, Bleehen NM, Lewis C: Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal cancer.Br J Cancer 60: 104–106, 1989

    Google Scholar 

  81. Baguley BC, Denny WA, Atwell GJ, Rewcastle GW, Ching LM, Thomsen LL, Zhuang L: Synthesis and properties of a new analogue of flavone acetic acid: 5,6-dimethyl xanthenone-4-acetic acid. Proc Am Assoc Cancer Res 81: 413, 1990

    Google Scholar 

  82. Henderson BW, Dougherty TJ: How does photodynamic therapy work? Photochem Photobiol 55: 145–157, 1992

    Google Scholar 

  83. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ: Tumour destruction and kinetics of tumour cell death in two experimental mouse tumours following photodynamic therapy. Cancer Res 45: 572–576, 1985

    Google Scholar 

  84. Weishaupt KR, Gomer CJ, Dougherty TJ: Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumour. Cancer Res 36: 2326–2329, 1976

    Google Scholar 

  85. Spikes JD: Phthalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumours. Photochem Photobiol 43:691–699, 1986

    Google Scholar 

  86. van Leir JE: Phthalocyanines as sensitizers for PDT of cancer. In: Kessel D (ed) Photodynamic Therapy of Neoplastic Disease. Vol 1. CRC Press,Boston,1990, pp279–289

    Google Scholar 

  87. Gonzalez S, Arnfield MR, Meeker BE, Tulip J, Lakey WH, Chapman JD: Treatment of Dunning R3327-AT rat prostate tumours with photodynamic therapy in combination with misonidazole. Cancer Res 46: 2858–2862,1986

    Google Scholar 

  88. Jori G: Photosensitized processes in vivo: Proposed phototherapeutic applications. Photochem Photobiol 52: 439–444, 1990

    Google Scholar 

  89. Tralau CJ, Barr H, MacRobert AJ, Bown SG: Relative merits of porphyrin and phthalocyanine sensitization for photodynamic therapy.In: Kessel D (ed) Photodynamic Therapy of Neoplastic Disease. Vol 1. CRC Press, Boston, 1990, pp263–277

    Google Scholar 

  90. Pope AJ, MacRobert AJ, Phillips D, Bown SG: The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy. Br J Cancer 64: 875–879, 1991

    Google Scholar 

  91. Bremner JCM, Adams GE, Pearson JK, Sansom JM, Stratford IJ, Bedwell J, Bown SG, MacRobert AJ, Phillips D: Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer 66: 1070–1076,1992

    Google Scholar 

  92. Mueller-Kleiser W, Schaefer C, Walenta S, Rofstad EK, Fenton BM,Sutherland RM: Assessment of tumour energy and oxygenation status by bioluminescence, nuclear magnetic resonance spectroscopy and cryospectrophotometry. Cancer Res 50: 1681–1690, 1990

    Google Scholar 

  93. Vaupel P, Okunieff P, Kallinowski F, Neuringer LJ: Correlation between 31P-NMR spectroscopy and tissue O2 tension measurements in a murine fibrosarcoma. Radiat Res 120: 477–485, 1989

    Google Scholar 

  94. Adams GE, Bremner JCM, Stratford, IJ, Wood PJ: Can31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygen status? Br J Radiol Suppl 24: 137–141, 1992

    Google Scholar 

  95. Bremner JCM, Counsell CJR, Adams GE, Stratford IJ, Wood PJ, Dunn JF, Radda GK:In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification. Br J Cancer 64: 862–866, 1991

    Google Scholar 

  96. Wood PJ, Stratford IJ, Sansom JM, Cattanach BM, Quinney RM, Adams GE: The response of spontaneous and transplantable murine tumours to vasoactive agents measured by31P magnetic resonance spectroscopy.Int J Radiat Oncol Biol Phys 22: 473–476, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Radiobiology Unit, OX13 ORD, Chilton, Didcot, Oxon, United Kingdom

    Jane C. M. Bremner

Authors
  1. Jane C. M. Bremner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bremner, J.C.M. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation. Cancer Metast Rev 12, 177–193 (1993). https://doi.org/10.1007/BF00689809

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689809

Key words

Search

Navigation